SREBF1 and fatty liver disease: This has been borne out in several studies [15–19], and we have proven that CAV1 overexpression by AAV2/8CAV1 treatment prevented LD feeding-induced hepatic steatosis and abnormal lipid metabolism by reducing SREBP1c expression via AMPK pathway activation[20] (Fig. 3B).